Kyu-Han Kim
Seoul, 110-744, South Korea
NCT Number: NCT02052531
The objective of this study was to find a clinically appropriate dose of PAC-14028 cream by comparatively evaluating the efficacy and safety of PAC-14028 cream of Amorepacific Corporation in patients with dermal pruritus.
Looking for future studies?
Notify Me20 year–65 year
All sexes
Interventional
Phase 2
Seoul, 110-744, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
Other names: PAC-14028 Cream 0.3%, PAC-14028 Cream 1.0%
Participants received topical Vehicle twice daily for 4 weeks
Other names: Vehicle of PAC-14028 Cream
Time frame: Baseline through Study Day 28
Patient reported outcome of pruritis measurement on a change in visual analog scale
Time frame: Baseline through Study Day 28
Time frame: Baseline through Study Day 28
Time frame: Baseline through Study Day 28
Time frame: Baseline through Study Day 28
Amorepacific Corporation
Industry
A Phase II, Single Center, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of PAC-14028 Cream in Dermal Pruritus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02565134
Skin Pruritus
Seoul, South Korea
View Trial DetailsNCT07580911
Dermatitis, Eczema Itch
View Trial Details